H.C. Wainwright initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $31 price target The firm believes RAP-219 could offer a “unique” clinical profile to address the unmet needs in epilepsy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP: